Status: Recruiting
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
The aim of this study is to evaluate the activity of first-line trastuzumab-deruxtecan, capecitabine and bevacizumab in terms of overall response rate for patients with HER-2 positive metastatic/locally advanced unresectable colorectal cancer
Participants needed: 42
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Gruppo Oncologico del Nord-OvestUpdated: Feb 17, 2026Locations: 28
Eligibility criteria
Written informed consent obtained from the patient/legal representative before p... [+31]
Have previously received any systemic anticancer therapy for CRC in the metastat... [+35]